GerdCare Medical Ltd, a company pioneering a new era in the global treatment of Gastroesophageal Reflux Disease (GERD). With over 1 billion people affected worldwide—and up to 40% unresponsive to existing drug therapies — GERD remains a critical and underserved health challenge. Current treatments, such as proton pump inhibitors (PPIs) and surgery, either mask symptoms without addressing the underlying cause or involve significant risks and low patient uptake. GerdCare is addressing this unmet clinical need. Our Breakthrough Solution GerdCare has developed the first-ever wearable, drug-free, non-invasive GERD treatment designed to restore the function of the gastroesophageal barrier—directly targeting the root cause of GERD, not just its symptoms. Our solution includes: • A smart wearable device delivering targeted electrical stimulation • A proprietary mobile app for personalized treatment optimization and tracking • A secure clinician dashboard enabling remote patient monitoring Clinically Validated Outcomes • Rapid symptom relief by significant reduction / normalization of esophageal acidity and GERD symptoms (such as heartburn and regurgitation) within 3–4 days • Up to 75% reduction in regurgitation, compared to approximately 10% - 15% with standard drug therapy • Excellent safety profile across proof-of-concept and pilot studies • Pivotal, FDA-approved clinical trial currently enrolling patients Market Opportunity • $6.3B+ global GERD therapeutics market, growing at 3.6% CAGR • 23M refractory patients in the US and EU alone • Razor-and-blade model with recurring consumables revenue • 80% gross margins and strong potential for both medical devices and pharma partnerships GerdCare holds multiple issued patents in the US, EU, Asia, IL.